Impact of Sodium-Glucose Cotransporter-2 Inhibitors in the Management of Chronic Kidney Disease: A Middle East and Africa Perspective

Elkeraie A. F., Al-Ghamdi S., Abu-Alfa A. K., Alotaibi T., Alsaedi A. J., Alsuwaida A., ...More

International Journal of Nephrology and Renovascular Disease, vol.17, pp.1-16, 2024 (ESCI) identifier identifier

  • Publication Type: Article / Article
  • Volume: 17
  • Publication Date: 2024
  • Doi Number: 10.2147/ijnrd.s430532
  • Journal Name: International Journal of Nephrology and Renovascular Disease
  • Journal Indexes: Emerging Sources Citation Index (ESCI), Scopus, EMBASE, Directory of Open Access Journals
  • Page Numbers: pp.1-16
  • Keywords: chronic kidney disease, nephrology referral, screening, sodium-glucose cotransporter-2 inhibitors
  • Hacettepe University Affiliated: Yes


Chronic kidney disease (CKD) is a major public health concern in the Middle East and Africa (MEA) region and a leading cause of death in patients with type 2 diabetes mellitus (T2DM) and hypertension. Early initiation of sodium-glucose cotransporter-2 inhibitors (SGLT-2i) and proper sequencing with renin-angiotensin-aldosterone system inhibitors (RAASi) in these patients may result in better clinical outcomes due to their cardioprotective properties and complementary mechanisms of action. In this review, we present guideline-based consensus recommendations by experts from the MEA region, as practical algorithms for screening, early detection, nephrology referral, and treatment pathways for CKD management in patients with hypertension and diabetes mellitus. This study will help physicians take timely and appropriate actions to provide better care to patients with CKD or those at high risk of CKD.